Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:385901.
doi: 10.1155/2014/385901. Epub 2014 Sep 11.

The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction

Eline Bredal Furenes  1 , Trine Baur Opstad  1 , Svein Solheim  2 , Ketil Lunde  3 , Harald Arnesen  1 , Ingebjørg Seljeflot  1
Affiliations

The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction

Eline Bredal Furenes et al. Mediators Inflamm. 2014.

Abstract

Background: Matrix metalloproteinase-9 (MMP-9), regulated by tissue inhibitor of metalloproteinase-9 (TIMP-1) and the extracellular matrix metalloproteinase inducer (EMMPRIN), contributes to plaque instability. Autologous stem cells from bone marrow (mBMC) treatment are suggested to reduce myocardial damage; however, limited data exists on the influence of mBMC on MMPs.

Aim: We investigated the influence of mBMC on circulating levels of MMP-9, TIMP-1, and EMMPRIN at different time points in patients included in the randomized Autologous Stem-Cell Transplantation in Acute Myocardial Infarction (ASTAMI) trial (n = 100). Gene expression analyses were additionally performed.

Results: After 2-3 weeks we observed a more pronounced increase in MMP-9 levels in the mBMC group, compared to controls (P = 0.030), whereas EMMPRIN levels were reduced from baseline to 2-3 weeks and 3 months in both groups (P < 0.0001). Gene expression of both MMP-9 and EMMPRIN was reduced from baseline to 3 months. MMP-9 and EMMPRIN were significantly correlated to myocardial injury (CK: P = 0.005 and P < 0.001, resp.) and infarct size (SPECT: P = 0.018 and P = 0.008, resp.).

Conclusion: The results indicate that the regulation of metalloproteinases is important during AMI, however, limited influenced by mBMC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gene expression of MMP-9 (a) and EMMPRIN (b) after 2-3 weeks and 3 months in the mBMC group and controls relative to baseline expression in the total population. Black bars: total group at baseline; grey bars: mBMC group; white bars: controls. ∗ indicates reduction from baseline to 3 months in the mBMC group P values refer to differences in expression relative to baseline between groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Stem cell treatment for acute myocardial infarction.
    Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Fisher SA, et al. Cochrane Database Syst Rev. 2015 Sep 30;2015(9):CD006536. doi: 10.1002/14651858.CD006536.pub4. Cochrane Database Syst Rev. 2015. PMID: 26419913 Free PMC article. Review.

References

    1. Gaziano JM. Global burden of cardiovascular disease. In: Bonow RO, Zipes DP, Libby P, editors. Braunwald’s Heart Disease. 7th edition. Philadelphia, Pa, USA: Elsevier Saunders; 2005. pp. 1–19.
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. - PubMed
    1. Apple FS, Wu AHA, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical Chemistry. 2005;51(5):810–824. - PubMed
    1. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701–705. - PubMed
    1. Peng C, Yang K, Xiang P, et al. Effect of transplantation with autologous bone marrow stem cells on acute myocardial infarction. International Journal of Cardiology. 2013;162(3):158–165. - PubMed

Publication types

MeSH terms